Stock BPMUF BASILEA PHARMACEUTICA AG
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Basilea Pharmaceutica AG OTC Markets

Equities

BPMUF

CH0011432447

Delayed OTC Markets
Other stock markets
 13:51:48 2024-05-20 EDT 		5-day change 1st Jan Change
48.15 USD +8.32% Intraday chart for Basilea Pharmaceutica AG 0.00% +17.44%
05-16 Basilea Pharmaceutica Receives Milestone Payment from Pfizer for Cresemba Sales MT
05-16 Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
GL
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GL
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GL
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
AQ
Actym Therapeutics Appoints Thomas Smart as CEO
PR
Basilea Pharmaceutica : Updated April 9, 2024
PU
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GL
Basilea Pharmaceutica : Updated April 4, 2024
PU
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
GL
Basilea Pharmaceutica : Updated April 3, 2024
PU
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
GL
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
AQ
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
GL
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
DJ
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
AQ
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GL
Cresemba(R) sales in Latin America trigger first sales milestone payment to Basilea
DJ
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
AQ
Basilea announces acquisition of preclinical antibiotics program from Spexis
GL
Basilea announces acquisition of preclinical antibiotics program from Spexis
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BSLN Stock
  4. BPMUF Stock
  5. News Basilea Pharmaceutica AG
  6. Press Releases